Company: NDRA
Filing Date: 2025-11-14
Form Type: 8-K
Source: 0001213900-25-110897
Chunk: 1

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 8-K
Item: Item 8.01
Chunk 1
---
 gross proceeds of up to
$1,750,000.

As a result of the Offering, as of the date of
this Current Report on Form 8-K, the Company believes it has regained compliance with the minimum $2.5 million stockholders’ equity
requirement for continued listing as set forth in the Rule.

Nasdaq will continue to monitor the Company’s
ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic report the Company does not
evidence compliance, it may be subject to delisting.

Forward-Looking Statements